Literature DB >> 23408116

The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure.

Michael H Court1, Marina Freytsis, Xueding Wang, Inga Peter, Chantal Guillemette, Suwagmani Hazarika, Su X Duan, David J Greenblatt, William M Lee.   

Abstract

Acetaminophen is cleared primarily by hepatic glucuronidation. Polymorphisms in genes encoding the acetaminophen UDP-glucuronosyltransferase (UGT) enzymes could explain interindividual variability in acetaminophen glucuronidation and variable risk for liver injury after acetaminophen overdose. In this study, human liver bank samples were phenotyped for acetaminophen glucuronidation activity and genotyped for the major acetaminophen-glucuronidating enzymes (UGTs 1A1, 1A6, 1A9, and 2B15). Of these, only three linked single nucleotide polymorphisms (SNPs) located in the shared UGT1A-3'UTR region (rs10929303, rs1042640, rs8330) were associated with acetaminophen glucuronidation activity, with rs8330 consistently showing higher acetaminophen glucuronidation at all the tested concentrations of acetaminophen. Mechanistic studies using luciferase-UGT1A-3'UTR reporters indicated that these SNPs do not alter mRNA stability or translation efficiency. However, there was evidence for allelic imbalance and a gene-dose proportional increase in the amount of exon 5a versus exon 5b containing UGT1A mRNA spliced transcripts in livers with the rs8330 variant allele. Cotransfection studies demonstrated an inhibitory effect of exon 5b containing cDNAs on acetaminophen glucuronidation by UGT1A1 and UGT1A6 cDNAs containing exon 5a. In silico analysis predicted that rs8330 creates an exon splice enhancer site that could favor exon 5a (over exon 5b) utilization during splicing. Finally, the prevalence of rs8330 was significantly lower (P = 0.027, χ(2) test) in patients who had acute liver failure from unintentional acetaminophen overdose compared with patients with acute liver failure from other causes or a race- or ethnicity-matched population. Together, these findings suggest that rs8330 is an important determinant of acetaminophen glucuronidation and could affect an individual's risk for acetaminophen-induced liver injury.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23408116      PMCID: PMC3629801          DOI: 10.1124/jpet.112.202010

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  41 in total

1.  Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity.

Authors:  Gonzalo Acuña; Dorothee Foernzler; Diane Leong; Michael Rabbia; Ralf Smit; Ernest Dorflinger; Rodolfo Gasser; Josephine Hoh; Jürg Ott; Edilio Borroni; Zung To; Annick Thompson; Jia Li; Lara Hashimoto; Klaus Lindpaintner
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

2.  Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity.

Authors:  Nathan R Jones; Dongxiao Sun; Willard M Freeman; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-06-01       Impact factor: 4.030

3.  Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

Authors:  Hugo Girard; Michael H Court; Olivier Bernard; Louis-Charles Fortier; Lyne Villeneuve; Qin Hao; David J Greenblatt; Lisa L von Moltke; Louis Perussed; Chantal Guillemette
Journal:  Pharmacogenetics       Date:  2004-08

4.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

5.  Inter-subject and ethnic differences in paracetamol metabolism.

Authors:  J A Critchley; G R Nimmo; C A Gregson; N M Woolhouse; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

6.  Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi.

Authors:  C J Henderson; C R Wolf; N Kitteringham; H Powell; D Otto; B K Park
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

7.  UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.

Authors:  Kimie Sai; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Noriko Katori; Hideto Jinno; Ryuichi Hasegawa; Nahoko Kaniwa; Jun-ichi Sawada; Kazuo Komamura; Kazuyuki Ueno; Shiro Kamakura; Masafumi Kitakaze; Yutaka Kitamura; Naoyuki Kamatani; Hironobu Minami; Atsushi Ohtsu; Kuniaki Shirao; Teruhiko Yoshida; Nagahiro Saijo
Journal:  Clin Pharmacol Ther       Date:  2004-06       Impact factor: 6.875

8.  Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype.

Authors:  S K Rauchschwalbe; M T Zühlsdorf; G Wensing; J Kuhlmann
Journal:  Int J Clin Pharmacol Ther       Date:  2004-02       Impact factor: 1.366

9.  ESEfinder: A web resource to identify exonic splicing enhancers.

Authors:  Luca Cartegni; Jinhua Wang; Zhengwei Zhu; Michael Q Zhang; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

10.  UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.

Authors:  Michael H Court; Qin Hao; Soundararajan Krishnaswamy; Tanios Bekaii-Saab; Abdul Al-Rohaimi; Lisa L von Moltke; David J Greenblatt
Journal:  J Pharmacol Exp Ther       Date:  2004-03-25       Impact factor: 4.030

View more
  31 in total

1.  Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study.

Authors:  Matthew W Linakis; Sarah F Cook; Shaun S Kumar; Xiaoxi Liu; Diana G Wilkins; Roger Gaedigk; Andrea Gaedigk; Catherine M T Sherwin; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

2.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Authors:  Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

Review 3.  Predicting and Understanding the Human Microbiome's Impact on Pharmacology.

Authors:  Reese Hitchings; Libusha Kelly
Journal:  Trends Pharmacol Sci       Date:  2019-06-03       Impact factor: 14.819

Review 4.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

5.  Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers.

Authors:  Michael H Court; Zhaohui Zhu; Gina Masse; Su X Duan; Laura P James; Jerold S Harmatz; David J Greenblatt
Journal:  J Pharmacol Exp Ther       Date:  2017-06-29       Impact factor: 4.030

Review 6.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

7.  Acetaminophen Hepatotoxicity.

Authors:  Anup Ramachandran; Hartmut Jaeschke
Journal:  Semin Liver Dis       Date:  2019-03-08       Impact factor: 6.115

8.  Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach.

Authors:  Ioannis Papageorgiou; Michael H Court
Journal:  Biochem Pharmacol       Date:  2017-04-19       Impact factor: 5.858

Review 9.  Drug-induced acute liver failure.

Authors:  William M Lee
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

10.  Combining heterogenous data for prediction of disease related and pharmacogenes.

Authors:  Christopher S Funk; Lawrence E Hunter; K Bretonnel Cohen
Journal:  Pac Symp Biocomput       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.